SCHEMBL7218316

SCHEMBL7218316

O=C(O)C1=Cc2cc(OCc3ccc(Cl)cc3)ccc2S(=O)(=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.47
MAOB P27338 7/20 0.43
MAOA P21397 6/20 0.43
KMT2A Q03164 2/20 0.42
SLC26A4 O43511 1/20 0.42
RXRA P19793 2/20 0.41
RXRB P28702 2/20 0.41
RXRG P48443 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
PPARA Q07869 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
PPARD Q03181 1/20 0.40
HPD P32754 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
SENP8 Q96LD8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7221889 0.90 NR4A2 (0.48) NR4A2MAOBMAOAKMT2ARXRA
SCHEMBL7216505 0.89 NPC1 (0.46) NR4A2MAOBMAOAKMT2ASLC26A4
SCHEMBL7223004 0.88 SMN1; SMN2 (0.43) NR4A2KMT2ARXRARXRBRXRG
SCHEMBL7216554 0.86 HRH3 (0.43) NR4A2KMT2ARXRARXRBRXRG
SCHEMBL7222916 0.85 RXRB (0.37) NR4A2MAOBMAOAKMT2ARXRA
SCHEMBL7221445 0.84 FFAR1 (0.39) NR4A2RXRARXRBRXRGMRGPRX4
SCHEMBL7215961 0.83 HRH3 (0.39) NR4A2KMT2ARXRARXRBRXRG
SCHEMBL7218103 0.83 NR4A2 (0.49) NR4A2MAOBMAOAKMT2ASLC26A4
SCHEMBL7222219 0.83 S1PR1 (0.41) RXRARXRBRXRGMRGPRX4NPC1
SCHEMBL7216431 0.81 MRGPRX4 (0.50) MAOBMRGPRX4NPC1RAB9APPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed